FDA Rare Disease Framework Puts CMC Review in Scope

On Oct 14, 2026, The FDA announced the Rare Disease Framework Initiative, an effort to build a fit-for-purpose approach to developing and reviewing drugs and biologics for rare diseases.¹ A new white paper describes the initiative, whose scope runs from pre-IND engagement through post-approval obligations and CMC requirements.

The Rare Disease Innovation Hub is leading the effort in partnership with the Office of the Commissioner, the Center for Biologics Evaluation and Research (CBER), and the Center for Drug Evaluation and Research (CDER).¹ The Office of Orphan Products Development, the Oncology Center of Excellence, and the Center for Devices and Radiological Health will also take part.

Why Is the FDA Standardizing Its Approach to Rare Disease Development?

According to the white paper, about 30 million Americans live with a rare disease, yet only about 5% of recognized rare diseases had an FDA-approved treatment as of 2025.¹ The FDA notes that roughly half of recent novel approvals from CDER and CBER have been for rare diseases but acknowledges that progress has not kept pace with need. The agency says it wants fit-for-purpose evidentiary expectations to become the norm for all rare disease applications, reflecting small populations, disease heterogeneity, and natural history that may be incomplete or poorly understood.

The initiative builds on existing efforts.¹ A 2024 Government Accountability Office report counted 18 FDA rare disease programs, and the white paper lists examples such as the Accelerating Rare disease Cures program and the Rare Disease Endpoint Advancement pilot.² The FDA says the framework will systematize those efforts into a consistently used, cross-center approach.

What Could Risk-Based CMC Review Mean for Manufacturing and Quality Teams?

One of the initiative’s guiding principles applies directly to manufacturing and quality teams.¹ The FDA says it will use risk-based approaches to CMC review and pre-approval inspections to support earlier patient access without compromising quality, safety, or effectiveness standards. The white paper does not define what those approaches will look like in practice, and it states that the framework adheres fully to the statutory requirements for safety and effectiveness.

Which Regulations and Guidance Documents Could Change?

The FDA says expected deliverables may include revisions to existing regulations or new regulatory provisions that embed fit-for-purpose evidentiary standards, along with a systematic review of existing guidance.¹ Any new or revised guidance could address endpoints, statistical approaches, trial design, patient engagement, external expert consultation, and post-approval obligations. The agency also plans to align review practices across CDER and CBER and to develop a training plan so reviewers and leadership apply the framework consistently.

How Can Sponsors and CDMOs Give Input on the Framework?

The FDA plans a public meeting, a Federal Register request for information, sector-specific roundtables with developers, advocacy groups, academic researchers, and clinicians, and internal feedback sessions with CDER and CBER review teams.¹ The agency has said it will host the public meeting Oct 28 at its White Oak campus in Maryland. The white paper sets no timeline for final deliverables, saying only that the FDA will take the time required to build a framework that is scientifically sound and legally durable.

What Should Teams Watch for Next?

For sponsors, CDMOs, and quality teams, the practical questions center on CMC.¹ How the FDA defines risk-based review and inspection for rare disease products, whether expectations converge between CDER and CBER, and whether new guidance addresses post-approval commitments will determine how much the initiative changes day-to-day development. Because rare disease programs often rely on small patient populations and limited batch experience, the initiative’s emphasis on early, clearly communicated expectations may place added importance on engaging the FDA about CMC strategy before the pivotal stage.

References

1. US Food and Drug Administration. FDA launches the Rare Disease Framework Initiative to develop a holistic, fit-for-purpose framework for rare disease drug development. October 14, 2026. Accessed October 14, 2026. https://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease
2. US Government Accountability Office. Performance and accountability report: fiscal year 2024. GAO-25-900570. November 15, 2024. Accessed October 14, 2026. https://www.gao.gov/products/gao-25-900570